上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。
Brequinar (Synonyms: DUP785; NSC 368390) 纯度: 99.75%
Brequinar (DUP785) 是一种有效的 dihydroorotate dehydrogenase (DHODH) 抑制剂,对人
Brequinar Chemical Structure
CAS No. : 96187-53-0
| 规格 | 价格 | 是否有货 | 数量 |
|---|---|---|---|
| Free Sample (0.1-0.5 mg) | Apply now | ||
| 10 mM * 1 mL in DMSO | ¥880 | In-stock | |
| 5 mg | ¥800 | In-stock | |
| 10 mg | ¥1300 | In-stock | |
| 50 mg | 询价 | ||
| 100 mg | 询价 |
* Please select Quantity before adding items.
Brequinar 相关产品
•相关化合物库:
- Drug Repurposing Compound Library Plus
- Clinical Compound Library Plus
- Bioactive Compound Library Plus
- Anti-Infection Compound Library
- Cell Cycle/DNA Damage Compound Library
- Immunology/Inflammation Compound Library
- Metabolism/Protease Compound Library
- Anti-Cancer Compound Library
- Clinical Compound Library
- Antiviral Compound Library
- Anti-Aging Compound Library
- Drug Repurposing Compound Library
- Ferroptosis Compound Library
- FDA Approved & Pharmacopeial Drug Library
- Mitochondria-Targeted Compound Library
| 生物活性 |
Brequinar (DUP785) is a potent inhibitor of dihydroorotate dehydrogenase (DHODH) with an IC50 of 5.2 nM for human DHODH. Brequinar has potent activities against a broad spectrum of viruses. Brequinar also has an anti-SARS2 activity. |
||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 体外研究 (In Vitro) |
Brequinar reduces virus progeny production by >90%, with EC50 of 17 nM. Brequinar (5 μM) also inhibits other orthopoxviruses, and blocks virus DNA replication. Brequinar does not affect virus early gene expression, but has a severe effect on the late stage of the virus cycle[1]. Brequinar reduces the level of envelope protein production and the viral titer in a dose-dependent manner, with EC50 of 78 nM in the CFI assay. Brequinar (5 μM) inhibits viral RNA synthesis. Brequinar has antiviral effect, but the effect is reversed by pyrimidine. Brequinar-resistant viruses can be selected in cell culture. Brequinar (5 μM) suppresses the luciferase activities from both the WT and NS5 mutant replicons[2]. Brequinar sodium effectively prevents the increase in PyNTP levels with an IC50 of 0.26 μM. Brequinar sodium effectively inhibits cell proliferation with an IC50 of 0.26 μM. Brequinar sodium inhibits autophosphorylation of p56lck with IC50 of 70 μM; inhibition is 39, 41, and 60% for 25, 50, and 100 μM Brequinar sodium, respectively. Brequinar sodium also inhibits the phosphorylation by p56lck of the exogenous substrate, histone 2B, with an IC50 of 70 μM; inhibition is 10, 43, 59, and 86% for 25, 50, 100, and 200 μM Brequinar sodium, respectively. Brequinar sodium inhibits autophosphorylation of p59fyn with an IC50 of 105 μM; inhibition is 0, 17, 48, and 65% for 25, 50, 100, and 200 μM Brequinar sodium, respectively. Brequinar sodium also inhibits the phosphorylation by p59fyn of histone 2B with an IC50 of 20 μM; inhibition is 26, 54, 79, 83, and 84% for 10, 25, 50, 100, and 200 μM Brequinar sodium, respectively[3]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||||||
| 体内研究 (In Vivo) |
Brequinar sodium-treated (10-20 mg/kg/day) mice has a 31% reduction in percentage of packed cell volume compared with untreated BALB/c mice. Brequinar sodium reduces UTP and CTP levels in bone marrow cells by 30 and 25%, respectively. Brequinar sodium (10-20 mg/kg/day) in combination with uridine (1000-2000 mg/kg/day) prevents anemia, and the hematocrits remain at levels (61-63%) comparable with those of untreated controls[3]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||||||
| Clinical Trial |
|
||||||||||||||||
| 分子量 |
375.37 |
||||||||||||||||
| Formula |
C23H15F2NO2 |
||||||||||||||||
| CAS 号 |
96187-53-0 |
||||||||||||||||
| 中文名称 |
布喹那 |
||||||||||||||||
| 运输条件 |
Room temperature in continental US; may vary elsewhere. |
||||||||||||||||
| 储存方式 |
|
||||||||||||||||
| 溶解性数据 |
In Vitro:
DMSO : 25 mg/mL (66.60 mM; Need ultrasonic) 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
|
||||||||||||||||
| 参考文献 |
|
| Kinase Assay [3] |
Immunoprecipitated p59fyn or p56lck from CTLL-4 cells or LSTRA cells (5×106) is preincubated with various concentrations of BQR in the PTK buffer (50 mM HEPES (pH 7.4), 10 mM MgCl2, and 10 mM MnCl2) on ice for 10 min. Exogenous substrate, histone 2B (2 μg), is added and, after 10 min, the reaction is initiated by addition of 10 μCi [γ-32P]ATP. After incubation at 20°C for 10 min, the reaction mixture is subjected to electrophoresis in a 12.5% SDS-polyacrylamide gel. Phosphorylation of the kinase and the exogenous substrate is analyzed by autoradiography. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
|---|---|
| Cell Assay [1] |
The neutral-red uptake assay is used to evaluate cell viability. BSC-40 cells are seeded in 96-well plates in the presence of concentrations of Brequinar ranging from 0.01 μM to 75 μM for 24 h. Control cells are incubated with 0.1% DMSO. Neutral red is methanol/acetic acid-extracted from cells and is quantitated at an absorbance of 490 nm (A490). All measurements expressed the average of four independent assays. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
| Animal Administration [3] |
Brequinar is administered once daily by i.p. injection, while uridine is administered twice daily. Mice are bled through the orbital vein using a microhematocrit capillary tube, and the blood is centrifuged for 10 min at 550 × g. The percentage of packed cell volumes is determined with a microhematocrit capillary tube reader. All mice are killed 4 h after receiving their last dose of Brequinar or uridine. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
| 参考文献 |
|
所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务